Oricell's $110M Pre-IPO Bet: A GPRC5D Challenger Emerges as the Myeloma CAR-T Race Heats Up

The myeloma CAR-T landscape is shifting from a BCMA monopoly to a multi-target battleground, and Oricell's substantial pre-IPO round is a direct wager on that transition. This capital is earmarked for the pivotal push of OriCAR-017, its autologous GPRC5D-targeting CAR-T, in relapsed/refractory multiple myeloma. The strategic timing is critical: while BCMA-targeting therapies like cilta-cel and ide-cel dominate, resistance and antigen loss are well-documented escape mechanisms. GPRC5D has emerged as the leading next-line target, with data showing efficacy even in BCMA-refractory patients. Oricell is not alone here—it faces direct competition from Johnson & Johnson's talquetamab and other clinical-stage GPRC5D CAR-Ts—but this funding level suggests investors see a credible contender with a potentially differentiated profile via its OriCAR platform, which may offer improved persistence or a more favorable safety signal.

The investor signal is one of conviction in a late-entry, high-value niche. Funding a pivotal program for an autologous CAR-T in 2026 requires belief not just in the target's biology, but in Oricell's ability to execute and differentiate in a crowded commercial and clinical field now dominated by large pharma. The sharp market observation is this: the myeloma therapy paradigm is rapidly evolving toward sequential and eventually combinatorial antigen targeting. Success for OriCAR-017 would position Oricell not as a BCMA replacement, but as a necessary component in the coming era of 'antigen cocktails' and treatment sequencing, a strategy that could justify a standalone commercial entity rather than an early trade-sale asset.